Want to see PCSA full AI Analyst Report?
PCSA Stock Chart & Stats
$0.12
-$0.13(-13.68%)
At close: 4:00 PM EST
$0.12
-$0.13(-13.68%)
Day’s Range― - ―
52-Week Range$1.76 - $14.25
Previous CloseN/A
Volume113.34K
Average Volume (3M)67.26K
Market Cap
$5.81M
Enterprise Value$3.18M
Total Cash (Recent Filing)$1.69M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.66
Shares Outstanding2,768,032
10 Day Avg. Volume56,510
30 Day Avg. Volume67,260
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.57K
Enterprise Value/Ebitda-0.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6
Revenue Forecast (FY)$10.01M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPositive interim data from the NGC-Cap mid-stage trial should constitute a meaningful value inflection point.
Financial StabilityThe company ended 2Q25 with roughly $6.9M in cash and cash equivalents, which is expected to be sufficient to fund operations into early 2026.
Strategic InvestmentsProcessa recently announced that it secured a strategic investment and is evaluating corporate cryptocurrency treasury strategies as part of its broader financial and growth objectives.
Bears Say
Financial ConstraintsAdditional capital will be required to fully fund the ongoing Phase 2 trial, and there is a concern that challenging financing conditions can limit the ability to complete the study.
Market ComplianceProcessa has received a notice from the NASDAQ exchange indicating that it is not currently in compliance with the minimum bid price requirement due to the low current share price.
Patient Enrollment DelaysThe required patients for the interim analysis of the Phase 2 trial have not enrolled yet, and it remains unclear when they will enroll due to the cash balance.
Processa Pharmaceuticals News
PCSA FAQ
What was Processa Pharmaceuticals, Inc.’s price range in the past 12 months?
Processa Pharmaceuticals, Inc. lowest stock price was $1.76 and its highest was $14.25 in the past 12 months.
What is Processa Pharmaceuticals, Inc.’s market cap?
Processa Pharmaceuticals, Inc.’s market cap is $5.81M.
When is Processa Pharmaceuticals, Inc.’s upcoming earnings report date?
Processa Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 29 days.
How were Processa Pharmaceuticals, Inc.’s earnings last quarter?
Processa Pharmaceuticals, Inc. released its earnings results on Nov 05, 2025. The company reported -$1.808 earnings per share for the quarter, beating the consensus estimate of -$2 by $0.192.
Is Processa Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Processa Pharmaceuticals, Inc.’s price is currently Overvalued.
Does Processa Pharmaceuticals, Inc. pay dividends?
Processa Pharmaceuticals, Inc. does not currently pay dividends.
What is Processa Pharmaceuticals, Inc.’s EPS estimate?
Processa Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Processa Pharmaceuticals, Inc. have?
Processa Pharmaceuticals, Inc. has 2,768,032 shares outstanding.
What happened to Processa Pharmaceuticals, Inc.’s price movement after its last earnings report?
Processa Pharmaceuticals, Inc. reported an EPS of -$1.808 in its last earnings report, beating expectations of -$2. Following the earnings report the stock price went down -1.734%.
Which hedge fund is a major shareholder of Processa Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in PCSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Processa's portfolio also features PCS12852, a unique selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. This compound is currently in Phase 2A clinical trials for its potential application in managing gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. Furthermore, the firm is advancing PCS3117, a cytosine analog, which has reached Phase 2B clinical trials for its use in pancreatic cancer and non-small cell lung cancer. Another candidate, PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase, is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. In addition, Processa is developing PCS11T, an analog derived from the drugs SN38 and irinotecan, intended for the treatment of diverse cancer types. The company was founded in 2011 and maintains its corporate headquarters in Hanover, Maryland.
Technical Analysis
Ownership Overview
3.84% Insiders
1.10% Mutual Funds
4.54% Other Institutional Investors
90.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---